Italian guidelines for the management of irritable bowel syndrome

Barbara, Giovanni; Cremon, Cesare; Bellini, Massimo; Corsetti, Maura; Nardo, Giovanni Di; Falangone, Francesca; Fuccio, Lorenzo; Galeazzi, Francesca; Iovino, Paola; Sarnelli, Giovanni; Savarino, Edoardo; Stanghellini, Vincenzo; Staiano, Annamaria; Stasi, Cristina; Tosetti, Cesare; Turco, Rosa; Ubaldi, Enzo; Zagari, Rocco Maurizio; Zenzeri, Letizia; Marasco, Giovanni

doi:10.1016/j.dld.2022.11.015

Cited by 28 publications

(28 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, since the diagnosis of DGBI, including IBS, is primarily made by a symptoms-based approach with alarm symptom exclusion and minimal diagnostic assessments, an accurate patient history and symptom characterisation may help in distinguishing between the above-mentioned conditions in order to avoid misdiagnosis. 9,10 We agree that COVID-19 is associated with the increased levels of stress, anxiety and depression, which may contribute to gastrointestinal and extra-intestinal symptom development and persistence. 5 Besides, it is recognised that DGBI and, particularly IBS, are associated with overlapping psychosocial illness.…”

Section: Letter: Post-covid-19 Disorders Of Gut-brain Interaction (Dg...mentioning

confidence: 85%

Letter: Post‐COVID‐19 disorders of gut–brain interaction (DGBI)—just post‐infectious or a multifaceted entity? Authors' reply

Marasco

Maida²,

Cremon

et al. 2023

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Letter: Post-covid-19 Disorders Of Gut-brain Interaction (Dg...mentioning

confidence: 85%

Letter: Post‐COVID‐19 disorders of gut–brain interaction (DGBI)—just post‐infectious or a multifaceted entity? Authors' reply

Marasco

Maida²,

Cremon

et al. 2023

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, due to the heterogeneity of trials on probiotics in terms of strains used, composition, design, and endpoints, 54,56–63 current guidelines suggest their use in IBS-D taken as a group, without suggesting specific strains or formulations 11,13 …”

Section: Global Ibs Symptomsmentioning

confidence: 99%

“…Its prevalence changes among different geographical regions due to variations in symptom interpretation and reporting 4 . IBS development, likely in genetically predisposed subjects, 5 can be triggered by a number of events, such as antibiotic exposure or other disruptors of gut physiology and microbiota such as an acute bout of gastrointestinal infection, 6–10 menses, diet, and psychological factors 11 . The pathophysiology of IBS includes several factors such as dysbiosis, increased intestinal permeability, mucosal immune activation, altered intestinal motor function, visceral hypersensitivity, and altered processing of information in the central nervous system 2,12–16 .…”

mentioning

confidence: 99%

Journal of Clinical Gastroenterology Lectureship Dubai 2022

Marasco,

Cremon,

Barbaro

et al. 2024

Journal of Clinical Gastroenterology

Self Cite

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) with diarrhea (IBS-D) affects ~1% of the general population and is characterized by abdominal pain associated with diarrhea. IBS-D symptoms significantly impact the quality of life of patients. Major uncertainties remain regarding the optimal management of these patients. Several therapies have been investigated over the years for the treatment of IBS-D. In the initial management, commonly prescribed approaches with an effect on global IBS symptoms include a low Fermentable Oligo-, Di-, Mono-Saccharides and Polyols diet and probiotics, while antispasmodics are used for targeting abdominal pain and loperamide for diarrhea only. Additional therapeutic options for the relief of global IBS symptoms include rifaximin, 5-HT3 antagonists, gut-directed psychological therapies, and eluxadoline, while tricyclic antidepressants can target abdominal pain and bile acid sequestrants diarrhea. Promising evidence exists for the use of mesalazine and fecal microbiota transplantation in IBS-D, although further evidence is needed for definitive conclusions regarding their efficacy.

show abstract

“…IBS therapy is challenging, and much more needs to be added to the research field[ 112 ]. In addition, naturally derived substances have repeatedly been considered possible therapies for IBS[ 113 - 115 ].…”

Section: H Erinaceus In Lower Gastrointestinal Tract Disease...mentioning

confidence: 99%

Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases

Gravina,

Pellegrino,

Auletta

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Hericium erinaceus is an edible and medicinal mushroom commonly used in traditional Chinese medicine for centuries. Several studies have highlighted its therapeutic potential for gastrointestinal disorders such as gastritis and inflammatory bowel diseases. In addition, some components of this mushroom appear to possess strong antineoplastic capabilities against gastric and colorectal cancer. This review aims to analyse all available evidence on the digestive therapeutic potential of this fungus as well as the possible underlying molecular mechanisms.

show abstract

Italian guidelines for the management of irritable bowel syndrome

Cited by 28 publications

References 221 publications

Letter: Post‐COVID‐19 disorders of gut–brain interaction (DGBI)—just post‐infectious or a multifaceted entity? Authors' reply

Letter: Post‐COVID‐19 disorders of gut–brain interaction (DGBI)—just post‐infectious or a multifaceted entity? Authors' reply

Journal of Clinical Gastroenterology Lectureship Dubai 2022

Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases

Contact Info

Product

Resources

About